Publication at Third Faculty of Medicine |
2023
Abstract
The treatment of bronchogenic carcinoma is continually enriched with new medications, the range of targeted drugs for individual driver mutations is expanding, and treatment standards are dynamically evolving. Our case report is not extraordinary in terms of rare genes or medications but serves as an example of the patient's resilience.
The patient's will to live, and optimism undeniably influenced our approach, enabling us to administer successive lines of treatment until we gradually reached a limit. The patient has finished seven rounds of treatment, and there could still be more to come.